Idioma:

Role of secondary cytoreductive surgery in ovarian cancer relapse: Who will benefit? A systematic analysis of 240 consecutive patients

Sehouli, Jalid ; Richter, R. ; Braicu, Elena Ioana ; Bühling, Kai J. ; Bahra, Marcus ; Neuhaus, Peter ; Lichtenegger, Werner ; Fotopoulou, Christina

Journal of surgical oncology, 2010-11, Vol.102 (6), p.656-662 [Revista revisada por pares]

Hoboken: Wiley Subscription Services, Inc., A Wiley Company

Texto completo disponible

Citas Citado por

Acciones

Título:
Role of secondary cytoreductive surgery in ovarian cancer relapse: Who will benefit? A systematic analysis of 240 consecutive patients
Autor: Sehouli, Jalid ; Richter, R. ; Braicu, Elena Ioana ; Bühling, Kai J. ; Bahra, Marcus ; Neuhaus, Peter ; Lichtenegger, Werner ; Fotopoulou, Christina
Materias: Adult ; Aged ; Aged, 80 and over ; Disease-Free Survival ; Drug Resistance, Neoplasm ; Female ; Humans ; Middle Aged ; Neoplasm Recurrence, Local - mortality ; Neoplasm Recurrence, Local - pathology ; Neoplasm Recurrence, Local - surgery ; Neoplasm, Residual - pathology ; ovarian cancer relapse ; Ovarian Neoplasms - mortality ; Ovarian Neoplasms - pathology ; Ovarian Neoplasms - surgery ; Platinum Compounds - pharmacology ; platinum resistance ; Prognosis ; secondary tumor debulking ; survival ; Treatment Outcome
Es parte de: Journal of surgical oncology, 2010-11, Vol.102 (6), p.656-662
Notas: ArticleID:JSO21652
The authors declare that there are no conflicts of interest.
ark:/67375/WNG-NZLWGXCB-K
istex:8DAF549BFFE7C600A2A8C56D465435BFAC461D37
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descripción: Background and Objectives In contrast to primary ovarian cancer, the value of surgery in relapsed‐OC (ROC) remains unclear. We evaluated surgical and clinical outcome of secondary cytoreduction in ROC. Methods All consecutive ROC patients who underwent secondary tumor‐debulking surgery were systematically analyzed as based on a validated intraoperative documentation tool. Tumor dissemination pattern, operative and clinical outcome were evaluated. Cox‐regression analysis was performed to identify independent predictors of mortality. Results Between 09/2000 and 10/2008, 240 operations were evaluated; 184 patients (81.1%) were platinum‐sensitive and 43 (20%) platinum‐resistant. 47.5% of the patients had ascites, while 85.8% presented a multifocal tumor dissemination pattern. In 53.8% a complete tumor resection was achieved; in another 24.2%, postoperative tumor residuals were <1 cm. In multivariate analysis, no tumor resection (HR: 7.6; 95% CI: 2.9–19.9), ascites >500 ml (HR: 6.76; 95% CI: 3.77–12.1), platinum resistance (HR: 3.1; 95% CI: 1.26–7.7), and initial FIGO stage IV (HR: 2.86; 95% CI: 1.16–7) were the most significant risk factors for mortality. Median OS was 42.3 months (95% CI: 24.37–60.2); 17.7 months (95% CI: 12.27–23.13); and 7.7 months (95% CI: 3.1–12.3) for patients with complete tumor resection, tumor residuals ≤1 and >1 cm, respectively (trend P‐value <0.001). Conclusions Absence of ascites, platinum‐sensitivity, initial FIGO stage <IV, and complete tumor resection correlate with a significantly better long‐term prognosis after ROC surgery. However, a significant trend of continuously improving survival associated with increasing tumor reduction rates could be identified even in patients where a complete tumor resection is not achievable. J. Surg. Oncol. 2010;102:656–662. © 2010 Wiley‐Liss, Inc.
Editor: Hoboken: Wiley Subscription Services, Inc., A Wiley Company
Idioma: Inglés

Enlaces

View this record in MEDLINE/PubMed

Volver a la lista de resultados

Anterior Resultado 7 Siguiente Ir a la siguiente página

Realización: Logos de Redes Sociales:

Role of secondary cytoreductive surgery in ovarian cancer relapse: Who will benefit? A systematic analysis of 240 consecutive patients

Sehouli, Jalid ; Richter, R. ; Braicu, Elena Ioana ; Bühling, Kai J. ; Bahra, Marcus ; Neuhaus, Peter ; Lichtenegger, Werner ; Fotopoulou, Christina

Hoboken: Wiley Subscription Services, Inc., A Wiley Company

Buscando en bases de datos remotas, por favor espere